Burkitt's lymphoma. A clinical study of 110 patients

✍ Scribed by F. K. Nkrumah; I. V. Perkins

• Publisher: John Wiley and Sons
• Year: 1976
• Tongue: English
• Weight: 467 KB
• Volume: 37
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(197602)37:2<671::aid-cncr2820370210>3.0.co;2-d

✦ Synopsis

O n e hundred and ten previously untreated patients with Burkitt's lymphoma were studied prospectively over a period ranging from over 1 year to 5 years. Of 103 patients who were treated with cyclophosphamide as a single agent, 79 (77%) achieved complete remission. Vincristine plus methotrexate o r cytosine arabinoside induced complete remissions in only two of 24 patients who failed to respond to cyclophosphamide. Fifty-two percent of patients who entered complete remission subsequently relapsed with tumor. Relapse was significantly higher in patients who presented with disseminated disease (Stage 111-IV) than in patients with localized disease (Stage 1-11). Patients who relapsed early (remission duration < 12 weeks) had a significantly worse prognosis than patients who relapsed late (remission duration > 12 weeks). Actuarial calculated 2-a n d 4-year survival for all patients was 44% and 38%, respectively. Factors that adversely affected survival were primary resistance to cyclophosphamide, early tumor relapse, central nervous system disease, and involvement of abdominal organs.